kras g12d inhibitor incb186748
Generic: KRAS G12D Inhibitor INCB186748
kras g12d inhibitor incb186748: 1 clinical trial tracked.
kras g12d inhibitor incb186748 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kras g12d inhibitor incb186748, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)
Interventionalopen30 enrolledStarted 2025-03Completion 2027-039 sites · United StatesIncyte Corporation